Multidisciplinary Alfred Psychiatry
research centre
Clinical Trials to treat cPTSD
Memantine
in cPTSD
​
Trial Objective
The Alison Project investigates the use of memantine 20mg (compared to placebo) in women with cPTSD and aims to improve symptom severity using validated and sensitive measures.
​
What's Involved?
The Alison Project is spread over two phases: Phase 1 started in April 2017 and was a ‘proof of concept’ pilot that examined the study design and procedures as well as preliminary data collected in order to ensure the best measures are used to test for improvements in cPTSD symptoms and that the study is feasible. Phase 2 will expand recruitment and address the question of whether memantine improves cognition, mood, quality of life and immunological biological inflammatory factors.
​
Who is eligible?
Women and men with a current diagnosis of complex post traumatic stress disorder or borderline personality disorder.
​
Chief Investigator: Professor Jayashri Kulkarni
​
​
Estradiol in
the treatment of cPTSD
Full title
A randomised placebo-controlled trial of estradiol for the treatment of women with complex post traumatic stress disorder (cPTSD), also known as borderline personality disorder (BPD).
​
About the Trial
​
Estradiol (estrogen) is an ovarian hormone that plays an important role in mood and thinking. Previous research has demonstrated that fluctuations of these hormones, or a sensitivity to such fluctuations may impact symptoms that are affected in CTD. Medications, drugs, and devices must be approved for use by the Australian Federal Government. Estradiol transdermal patch is approved for marketing by the Therapeutic Goods Administration (TGA) in Australia. It should be noted that estrogen has not been approved for use in the treatment of complex trauma disorder in Australia or other countries, and this study investigating these hormones for treatment of CTD symptoms is considered experimental.
